Besponsa 1mg Injection

About

Besponsa 1mg Injection (inotuzumab ozogamicin) is an antibody-drug conjugate (ADC) composed of a humanized anti-CD22 monoclonal antibody covalently linked to calicheamicin, a potent cytotoxic agent. The antibody targets CD22, a protein highly expressed on the surface of B-cell acute lymphoblastic leukemia (ALL) cells. Upon binding to CD22, the ADC is internalized into the cell, where calicheamicin is released. This cytotoxic payload then causes DNA double-strand breaks, leading to cell cycle arrest and subsequent apoptotic cell death. This targeted delivery mechanism allows for potent anti-leukemic activity while minimizing systemic exposure to the cytotoxic agent, making it an effective treatment for relapsed or refractory B-cell precursor ALL.

Uses

• Relapsed or refractory B-cell precursor ALL
• Adult patients with ALL
• Patients ineligible for stem cell transplant
• As a bridge to stem cell transplant

Directions For Use

Administered intravenously by a qualified healthcare professional. Premedication is required to reduce infusion-related reactions.

Benefits

• Targets CD22-positive leukemia cells
• Delivers potent cytotoxic agent directly to cancer cells
• Induces high rates of remission in relapsed/refractory ALL
• Offers a treatment option for difficult-to-treat ALL
• May serve as a bridge to stem cell transplantation
• Improved overall response rates

Side Effects

• Hepatotoxicity (including veno-occlusive disease)
• Myelosuppression (neutropenia, thrombocytopenia)
• Infusion-related reactions
• Fever
• Nausea
• Fatigue
• Abdominal pain
• Headache
• Elevated transaminases
• Hyperbilirubinemia
• Peripheral neuropathy
• Stomatitis

Safety Measures

• Alcohol - No specific interaction, but avoid excessive alcohol due to potential for liver toxicity, which is a significant concern with this drug.
• Pregnancy - Contraindicated in pregnancy; use effective contraception during and for at least 8 months after treatment.
• Breastfeeding - Not recommended; discontinue breastfeeding during treatment and for at least 2 months after the last dose.
• Liver - High risk of hepatotoxicity, including veno-occlusive disease (VOD). Close monitoring of liver function is crucial.
• Kidney - Use with caution in patients with renal impairment; monitor renal function closely.
• Lung - Monitor for pulmonary adverse events, though less common, and manage promptly if they occur.

Disclaimer

MedEHub is committed to delivering reliable, expert-reviewd information to help consumers make informed health decisions. However, the content provided on this website is for informational purposes only and is not intended to replace professional medical advice, diagnosis or treatment.

Always consult your doctor for any medical concerns, and discuss your questions about health conditions or medications with a qualified healthcare professional. Do not ignore or delay seeking professional medical advice based on information found on Med E Hub.

Our goal is to complement, not replace, the essential doctor-patient relationship.